These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1041 related items for PubMed ID: 16189291

  • 1. Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure.
    Costello-Boerrigter LC, Smith WB, Boerrigter G, Ouyang J, Zimmer CA, Orlandi C, Burnett JC.
    Am J Physiol Renal Physiol; 2006 Feb; 290(2):F273-8. PubMed ID: 16189291
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Comparison of the effects of tolvaptan and furosemide on renal water and sodium excretion in patients with heart failure and advanced chronic kidney disease: a subanalysis of the K-STAR study.
    Tominaga N, Kida K, Inomata T, Sato N, Izumi T, Akashi YJ, Shibagaki Y.
    Clin Exp Nephrol; 2018 Dec; 22(6):1395-1403. PubMed ID: 29934667
    [Abstract] [Full Text] [Related]

  • 5. Safety of add-on tolvaptan in patients with furosemide-resistant congestive heart failure complicated by advanced chronic kidney disease: a sub-analysis of a pharmacokinetics/ pharmacodynamics study.
    Tominaga N, Kida K, Matsumoto N, Akashi YJ, Miyake F, Kimura K, Shibagaki Y.
    Clin Nephrol; 2015 Jul; 84(1):29-38. PubMed ID: 25997504
    [Abstract] [Full Text] [Related]

  • 6. Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial.
    Gheorghiade M, Niazi I, Ouyang J, Czerwiec F, Kambayashi J, Zampino M, Orlandi C, Tolvaptan Investigators.
    Circulation; 2003 Jun 03; 107(21):2690-6. PubMed ID: 12742979
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Effect of tolvaptan on renal water and sodium excretion and blood pressure during nitric oxide inhibition: a dose-response study in healthy subjects.
    Al Therwani S, Rosenbæk JB, Mose FH, Bech JN, Pedersen EB.
    BMC Nephrol; 2017 Mar 13; 18(1):86. PubMed ID: 28288570
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. In chronic heart failure with marked fluid retention, the i.v. high doses of loop diuretic are a predictor of aggravated renal dysfunction, especially in the set of heart failure with normal or only mildly impaired left ventricular systolic function.
    De Vecchis R, Ciccarelli A, Ariano C, Cioppa C, Giasi A, Pucciarelli A, Cantatrione S.
    Minerva Cardioangiol; 2011 Dec 13; 59(6):543-54. PubMed ID: 21330961
    [Abstract] [Full Text] [Related]

  • 14. Effects of tolvaptan on volume overload in Japanese patients with heart failure: results of a phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.
    Matsuzaki M, Hori M, Izumi T, Asanoi H, Tsutamoto T, Tolvaptan Investigators.
    Cardiovasc Drugs Ther; 2011 Dec 13; 25 Suppl 1():S19-31. PubMed ID: 22120091
    [Abstract] [Full Text] [Related]

  • 15. Effect of vasopressin antagonism on renal handling of sodium and water and central and brachial blood pressure during inhibition of the nitric oxide system in healthy subjects.
    Al Therwani S, Mose FH, Jensen JM, Bech JN, Pedersen EB.
    BMC Nephrol; 2014 Jun 25; 15():100. PubMed ID: 24965902
    [Abstract] [Full Text] [Related]

  • 16. Renal effects of conivaptan, furosemide, and the combination in patients with chronic heart failure.
    Goldsmith SR, Gilbertson DT, Mackedanz SA, Swan SK.
    J Card Fail; 2011 Dec 25; 17(12):982-9. PubMed ID: 22123359
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Administration of tolvaptan with reduction of loop diuretics ameliorates congestion with improving renal dysfunction in patients with congestive heart failure and renal dysfunction.
    Hanatani A, Shibata A, Kitada R, Iwata S, Matsumura Y, Doi A, Sugioka K, Takagi M, Yoshiyama M.
    Heart Vessels; 2017 Mar 25; 32(3):287-294. PubMed ID: 27385022
    [Abstract] [Full Text] [Related]

  • 20. Effects of nonpeptide vasopressin V2 antagonist tolvaptan in rats with heart failure.
    Veeraveedu PT, Watanabe K, Ma M, Palaniyandi SS, Yamaguchi K, Suzuki K, Kodama M, Aizawa Y.
    Biochem Pharmacol; 2007 Nov 15; 74(10):1466-75. PubMed ID: 17720144
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 53.